-
公开(公告)号：US20190381011A1
公开(公告)日：2019-12-19
申请号：US16230033
申请日：2018-12-21
Applicant: Novartis AG
Inventor： Kamlesh Jagdis BALA , Andrew BREARLEY , James DALE , Anne-Marie EDWARDS , Mahbub AHMED , David PORTER , Robert Alexander PULZ , Lisa Ann ROONEY , David Andrew SANDHAM , Duncan SHAW , Nichola SMITH , Jessica Louise TAYLOR , Roger John TAYLOR , Thomas Josef Troxler , Joe WRIGGLESWORTH
IPC: A61K31/422 , C07D413/14 , A61K31/4155 , C07D413/12
Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
-
公开(公告)号：US20140113914A1
公开(公告)日：2014-04-24
申请号：US13657001
申请日：2012-10-22
Applicant: NOVARTIS AG
Inventor： Gurdip BHALAY , Lee EDWARDS , Catherine HOWSHAM , Peter HUNT , Nichola SMITH
IPC: C07D471/10 , A61P11/00 , A61K31/497
CPC classification number: A61K31/497 , C07D471/10
Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
Abstract translation: 式I化合物及其药学上可接受的盐和溶剂合物，其中R1，R2，R3，R4，R5，R6，R7，R8，R9和R10具有说明书中所示的含义，可用于治疗由 阻断上皮钠通道。 还描述了含有化合物的药物组合物和用于制备化合物的方法。
-
公开(公告)号：US20230301970A1
公开(公告)日：2023-09-28
申请号：US18317990
申请日：2023-05-16
Applicant: Novartis AG
Inventor： Kamlesh Jagdis BALA , Andrew BREARLEY , James DALE , Anne-Marie EDWARDS , Mahbub AHMED , David PORTER , Robert Alexander PULZ , Lisa Ann ROONEY , David Andrew SANDHAM , Duncan SHAW , Nichola SMITH , Jessica Louise TAYLOR , Roger John TAYLOR , Thomas Josef TROXLER-SCHWAB , Joe WRIGGLESWORTH
IPC: A61K31/422 , C07D413/14 , A61K31/4155 , C07D413/12
CPC classification number: A61K31/422 , C07D413/14 , A61K31/4155 , C07D413/12
Abstract: The present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof;
a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.-
公开(公告)号：US20200268718A1
公开(公告)日：2020-08-27
申请号：US16874595
申请日：2020-05-14
Applicant: Novartis AG
Inventor： Kamlesh Jagdis BALA , Andrew BREARLEY , James DALE , Anne-Marie EDWARDS , Mahbub AHMED , David PORTER , Robert Alexander PULZ , Lisa Ann ROONEY , David Andrew SANDHAM , Duncan SHAW , Nichola SMITH , Jessica Louise TAYLOR , Roger John TAYLOR , Thomas Josef TROXLER , Joe WRIGGLESWORTH
IPC: A61K31/422 , C07D413/14 , A61K31/4155 , C07D413/12
Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
-
公开(公告)号：US20170143705A1
公开(公告)日：2017-05-25
申请号：US15369133
申请日：2016-12-05
Applicant: NOVARTIS AG
Inventor： Gurdip BHALAY , Lee EDWARDS , Catherine HOWSHAM , Peter HUNT , Nichola SMITH
IPC: A61K31/497
CPC classification number: A61K31/497 , C07D471/10
Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
-
Patent Agency Ranking
公开(公告)号：US20170014388A1
公开(公告)日：2017-01-19
申请号：US15184730
申请日：2016-06-16
Applicant: Novartis AG
Inventor： Kamlesh Jagdis BALA , Andrew BREARLEY , James DALE , Anne-Marie EDWARDS , Mahbub AHMED , David PORTER , Robert Alexander PULZ , Lisa Ann ROONEY , David Andrew SANDHAM , Duncan SHAW , Nichola SMITH , Jessica Louise TAYLOR , Roger John TAYLOR , Thomas Josef Troxler , Joe WRIGGLESWORTH
IPC: A61K31/422
CPC classification number: A61K31/422 , A61K31/4155 , C07D413/12 , C07D413/14 , A61K2300/00
Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Abstract translation: 制备本发明化合物的方法及其治疗用途。 本发明还提供药理活性剂和药物组合物的组合。
-
公开(公告)号：US20250034108A1
公开(公告)日：2025-01-30
申请号：US18764471
申请日：2024-07-05
Applicant: NOVARTIS AG
Inventor： Robert Francis DAY , Hatice Belgin GULGEZE EFTHYMIOU , Adam FRIEDMAN , Tyler HARRISON , Jay Francis LARROW , Yunshan PENG , Nichola SMITH , Haihao TANG , Yanxiang WU , Sandra Marie KING , Sii Hong LAU , Tajesh PATEL
IPC: C07D401/04 , A61K31/41 , A61K31/4439 , C07D257/04
Abstract: The present disclosure relates to sulfonamide compounds, the use thereof for modulating the sodium channel Nav1.5 and methods of treating or preventing diseases, disorders, or conditions using the same.
-
公开(公告)号：US20220306617A1
公开(公告)日：2022-09-29
申请号：US17638106
申请日：2020-08-24
Applicant: NOVARTIS AG
Inventor： Claire ADCOCK , Jake AXFORD , Ying HOU , Hyungchul KIM , Yiping SHEN , Nichola SMITH , Catherine Fooks SOLOVAY , Moo Je SUNG , Megan LIGHTFOOT , Alessandro MAZZACANI , Emily STANLEY , Lewis WHITEHEAD
IPC: C07D413/10 , A61K31/422 , A61K45/06 , C07D413/14 , A61K31/454 , A61K31/5377 , A61K31/675 , C07F9/6558 , A61P11/00
Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the ctivity of TMEM16a. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including COPD, bronchiectasis, asthma, cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, cystic fibrosis, primary ciliary dyskinesia, respiratory tract infections (acute and chronic; viral and bacterial), lung carcinoma.
-
公开(公告)号：US20220251067A1
公开(公告)日：2022-08-11
申请号：US17574820
申请日：2022-01-13
Applicant: Novartis AG
Inventor： Christopher FARADY , Nina GOMMERMANN , Philipp JANSER , Angela MACKAY , Henri MATTES , Nichola SMITH , Catherine Fooks SOLOVAY , Nikolaus Johannes STIEFL , Eric VANGREVELINGHE , Juraj VELCICKY , Anette von MATT
IPC: C07D401/12 , C07D237/14 , C07D237/20 , C07D403/12 , C07D413/12 , C07D451/04
Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
-
公开(公告)号：US20210052554A1
公开(公告)日：2021-02-25
申请号：US17089064
申请日：2020-11-04
Applicant: Novartis AG
Inventor： Kamlesh Jagdis BALA , Andrew BREARLEY , James DALE , Anne-Marie EDWARDS , Mahbub AHMED , David PORTER , Robert Alexander PULZ , Lisa Ann ROONEY , David Andrew SANDHAM , Duncan SHAW , Nichola SMITH , Jessica Louise TAYLOR , Roger John TAYLOR , Thomas Josef Troxler , Joe WRIGGLESWORTH
IPC: A61K31/422 , C07D413/14 , A61K31/4155 , C07D413/12
Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.015 seconds)
